Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Terminated 2 Recruiting 2 Withdrawn 1 Suspended 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Hereditary Sensory and Autonomic Neuropathies 1 Colorectal Neoplasms 1 Brain Neoplasms 1

Interventions

Radiosurgery 7 Oxaliplatin 7 Docetaxel 7 Paclitaxel 5 Fluorouracil 5 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 4 Carboplatin 4 Capecitabine 4 Trastuzumab 3 Radiotherapy 3 Radiation 3 Leucovorin 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3 Cetuximab 3 Bevacizumab 3 spartalizumab 2 sipuleucel-T 2 repotrectinib 2 pembrolizumab 2 pazopanib 2 orteronel 2 fludarabine 2 atezolizumab 2 aldesleukin 2 Temozolomide 2 Surveys and Questionnaires 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasm Metastasis × neratinib × Clear all

NCT04901299 2023-08-01

HER2-Signal

Massachusetts General Hospital

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡